Ponatinib (AP24534)

For research use only. Not for use in humans.

目录号：S1490

CAS No. 943319-70-8

Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 819.31	现货
10mg	RMB 903.01	现货
50mg	RMB 3034.48	现货
200mg	RMB 7959.08	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ponatinib (AP24534)发表文献101篇：

Nature, 2020, 583(7818):845-851

PubMed: 32699415 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4370

PubMed: 32873792 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.32924

PubMed: 32064608 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

J Infect Dis, 2020, 3;jiaa295

PubMed: 32492702 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 30;11:543

PubMed: 32425788 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):592

PubMed: 32580713 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Nature, 2020, 583(7818):845-851

PubMed: 32699415 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:408

PubMed: 32596239 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020, 1;6(2) pii: a004838

PubMed: 31980503 ( click the link to review the publication )
Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )
Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Blood, 2016, 28;127(17):2131-43

PubMed: 26864341 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )
Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )
Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

产品描述

靶点

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	点击更多
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	点击更多

体外研究

Ponatinib是有效的可用于口服的多靶点激酶抑制剂，作用于野生型细胞,及T315I 突变细胞IC50分别为1.2和8.8nM。^[1] Ponatinib抑制Ba/F3衍生细胞系的增殖。^[2] Ponatinib作用于表达野生型或T315I突变型BCR-ABL的CML细胞系，有效抑制BCR-ABL调节的信号。Ponatinib阻断在细胞瘤筛选时产生抗性突变。^[3] Ponatinib也抑制VEGFR和FGFR家族激酶，在体外抑制FLT3, KIT, FGFR1,和PDGFRa激酶活性时IC50分别为13, 13, 2, 和1 nM.^[4]Ponatinib抑制全部4种RTKs磷酸化，存在剂量依赖性，IC50值为0.3到20 nM。然而，Ponatinib抑制表达野生型FLT3的RS4;11细胞时IC50>100 nM。

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M4P2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTVNZAzUUN3ME2wMlAxODByMECzOVkh\|ryP	MXHTRW5ITVJ?
MV-4-11	M4LWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMECwNFk2PiEQvF2=	MofpV2FPT0WU
MEG-01	NYjZWFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWf3NGdWUUN3ME2wMlAxODF{ODFOwG0>	MnXEV2FPT0WU
LAMA-84	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfSRVdKSzVyPUCuNFAxOTZ3IN88US=>	NHL4[41USU6JRWK=
CGTH-W-1	M3[3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMECxOlkh\|ryP	NFPN[oxUSU6JRWK=
KASUMI-1	M3;N[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33OOGlEPTB;MD6wNFIyPyEQvF2=	MlHqV2FPT0WU
BE-13	M4\SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMECyOVkh\|ryP	NUCxeplmW0GQR1XS
CTV-1	M3uxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\1XFVKSzVyPUCuNFA2OjFizszN	MkTGV2FPT0WU
NKM-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEC2OVUh\|ryP	M3jCRnNCVkeHUh?=
MONO-MAC-6	NUHVdFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3B[\|JLUUN3ME2wMlAxQDN5IN88US=>	MVzTRW5ITVJ?
A204	NFTodXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDUVYp3UUN3ME2wMlAyOjF6IN88US=>	MorXV2FPT0WU
GDM-1	M3ixWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMEG4N\|Mh\|ryP	M{fPXXNCVkeHUh?=
AN3-CA	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnT6TWM2OD1yLkCxPFc{KM7:TR?=	Mn7jV2FPT0WU
BL-70	NXrxbHBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGP3cXpKSzVyPUCuNFIyQTlizszN	MnWzV2FPT0WU
Daudi	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH2TWM2OD1yLkCyOVM4KM7:TR?=	M{n3cHNCVkeHUh?=
KU812	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;PS49KSzVyPUCuNFI5PDhizszN	MWXTRW5ITVJ?
KG-1	NX65RVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDBU\|NKSzVyPUCuNFMzQTRizszN	MlzGV2FPT0WU
DOHH-2	NH3y[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TwUmlEPTB;MD6wOFgxOyEQvF2=	MULTRW5ITVJ?
HuO9	NELW[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfLTGNKSzVyPUCuNFU1PDhizszN	NVrJfIc5W0GQR1XS
EB2	NU\zNpJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nkVWlEPTB;MD6wOVU4PiEQvF2=	Mn:2V2FPT0WU
G-402	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYmwV2JOUUN3ME2wMlA3OzRzIN88US=>	M{DFW3NCVkeHUh?=
SU-DHL-1	M2\5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfYTWM2OD1yLkC2N\|c6KM7:TR?=	MYrTRW5ITVJ?
NCI-H719	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLyTWM2OD1yLkC3PFg5KM7:TR?=	M2rDR3NCVkeHUh?=
MLMA	NUfFRnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYOzO\|dsUUN3ME2wMlA6ODZizszN	MVjTRW5ITVJ?
KM12	NFi5WWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLyTWM2OD1yLkC5O\|M4KM7:TR?=	MY\TRW5ITVJ?
SUP-T1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMEm5PFIh\|ryP	M{fGUnNCVkeHUh?=
MZ1-PC	NX3BdoxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojaTWM2OD1yLkGxN\|M3KM7:TR?=	MmS1V2FPT0WU
MFE-296	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLETWM2OD1yLkGxPFM6KM7:TR?=	NUnM[\|N6W0GQR1XS
ALL-PO	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXOWYxKSzVyPUCuNVI1PDNizszN	NYjVcIhqW0GQR1XS
GB-1	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjRTWM2OD1yLkGyOVEzKM7:TR?=	NWKyUI5HW0GQR1XS
SIG-M5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknYTWM2OD1yLkGzN\|ch\|ryP	NWPheXExW0GQR1XS
P30-OHK	NVfkcI9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFW0OYhKSzVyPUCuNVU3PzJizszN	M4K4VXNCVkeHUh?=
NCI-H716	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjHemgyUUN3ME2wMlE3OjZ4IN88US=>	NFzqfXNUSU6JRWK=
MPP-89	M1znN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMU[5N\|Mh\|ryP	NF3YSWFUSU6JRWK=
SF126	NWG0bGxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoH4TWM2OD1yLkG3NFY{KM7:TR?=	MXHTRW5ITVJ?
CTB-1	NF:zSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfvZm9KUUN3ME2wMlE4OzF4IN88US=>	NWXaUHJiW0GQR1XS
CA46	M{HrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTHTWM2OD1yLkG3OFg6KM7:TR?=	NEnC[HZUSU6JRWK=
NCI-H520	NGfoeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;EbnR3UUN3ME2wMlE4PzN{IN88US=>	Ml7kV2FPT0WU
CAL-85-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPkTWM2OD1yLkG3PVI4KM7:TR?=	NGnMSm9USU6JRWK=
NCI-H2342	M4jJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMUi1O\|ch\|ryP	NF\oPZpUSU6JRWK=
697	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\pTWM2OD1yLkG4PFcyKM7:TR?=	MnTSV2FPT0WU
NY	M1\wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMUmyPFch\|ryP	MonJV2FPT0WU
T98G	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4T3UGlEPTB;MD6xPVMyQCEQvF2=	NUe0WFlzW0GQR1XS
NCI-H1703	NH;sS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjH[WlVUUN3ME2wMlE6PjF3IN88US=>	M36xNHNCVkeHUh?=
NCI-H2087	NIryUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPDbIw6UUN3ME2wMlIxPDN7IN88US=>	NWTGSYt{W0GQR1XS
PF-382	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHq4SnZKSzVyPUCuNlA5PzNizszN	NIP1dnJUSU6JRWK=
HCT-116	MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3CfXBPUUN3ME2wMlIyODZ7IN88US=>	MUHTRW5ITVJ?
CAKI-1	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4X2[WlEPTB;MD6yNVY3PiEQvF2=	NH6xNmRUSU6JRWK=
CCF-STTG1	M3r1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XhSWlEPTB;MD6yNlQ4PSEQvF2=	M4fCc3NCVkeHUh?=
D-392MG	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFv2PIFKSzVyPUCuNlMyPzdizszN	M1f2fXNCVkeHUh?=
RT-112	NUjGRZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPhN2VXUUN3ME2wMlI{Pzl3IN88US=>	M4W3dXNCVkeHUh?=
MES-SA	M3HFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTUTm9FUUN3ME2wMlI1OTh5IN88US=>	NHi2dpNUSU6JRWK=
LC-2-ad	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjmXpJKSzVyPUCuNlQzPjVizszN	MXnTRW5ITVJ?
NOS-1	M{fKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPwZ4Q1UUN3ME2wMlI1OzZ5IN88US=>	MkDjV2FPT0WU
NALM-6	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLJdJJtUUN3ME2wMlI2PTR\|IN88US=>	M4LkenNCVkeHUh?=
TE-15	NXrKTI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMk[wPVEh\|ryP	MVTTRW5ITVJ?
786-0	NX\yUHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DFSGlEPTB;MD6yOlIzQCEQvF2=	M2TGXnNCVkeHUh?=
IST-MES1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\2eXVKSzVyPUCuNlY5OjlizszN	NEGx[3JUSU6JRWK=
KYSE-180	NHT1dG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HwUmlEPTB;MD6yOlg6OSEQvF2=	NGW1VG5USU6JRWK=
YT	NYPqOWp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDzOYdSUUN3ME2wMlI3QTd2IN88US=>	MUTTRW5ITVJ?
A427	NYC3fXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L4emlEPTB;MD6yO\|I3PCEQvF2=	MlvrV2FPT0WU
KYSE-450	NHruNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX0[2pVUUN3ME2wMlI4OzJ7IN88US=>	NUXMXm9sW0GQR1XS
HuH-7	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV36UZBqUUN3ME2wMlI4PzZ\|IN88US=>	NIDQfIVUSU6JRWK=
CAS-1	M4LMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEiwd4RKSzVyPUCuNlg{ODNizszN	MVPTRW5ITVJ?
KURAMOCHI	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTtZYhMUUN3ME2wMlI5PDF7IN88US=>	MUTTRW5ITVJ?
ACHN	NGrudotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvwTWM2OD1yLkK5N\|I{KM7:TR?=	NGP3SoVUSU6JRWK=
HGC-27	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMkmzOVMh\|ryP	MVnTRW5ITVJ?
A172	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMkm1O\|ch\|ryP	NH\EZodUSU6JRWK=
SNU-449	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjWe2ZKSzVyPUCuNlk6PjRizszN	M4DXT3NCVkeHUh?=
SW982	NIPib4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDPTWM2OD1yLkK5PVc5KM7:TR?=	M2O1SnNCVkeHUh?=
EFO-21	NYXEfFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHroTlJKSzVyPUCuN\|A1OTFizszN	NX3uNZcxW0GQR1XS
NCI-H2030	M1rNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwM{GxOlQh\|ryP	NELiVotUSU6JRWK=
HT-144	M1vzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXCOoduUUN3ME2wMlMyOjhizszN	MlL1V2FPT0WU
MFE-280	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnaTGhsUUN3ME2wMlMyPDV\|IN88US=>	NILscYdUSU6JRWK=
SK-LU-1	NFr2c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXWe5VKSzVyPUCuN\|E1PjZizszN	NEXRdY9USU6JRWK=
NCI-H2052	NIrOUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfwTWM2OD1yLkOxOFg1KM7:TR?=	M3PSO3NCVkeHUh?=
SK-HEP-1	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwM{OzOlgh\|ryP	MYXTRW5ITVJ?
QIMR-WIL	NW\iXYxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDRfGpKSzVyPUCuN\|M1OjRizszN	Ml;6V2FPT0WU
A2780	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDub29KSzVyPUCuN\|Q{ODRizszN	MkLCV2FPT0WU
ACN	M3nGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[yTWM2OD1yLkO0PFc{KM7:TR?=	NFnWVW5USU6JRWK=
BxPC-3	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwM{S5PFkh\|ryP	MVvTRW5ITVJ?
BCPAP	M2HaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwM{[wNFEh\|ryP	M2[xfnNCVkeHUh?=
HOP-62	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXCc2xIUUN3ME2wMlM3OTB4IN88US=>	MUTTRW5ITVJ?
SW1710	NHrScnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwM{[0OVUh\|ryP	MYTTRW5ITVJ?
OPM-2	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnyUohKSzVyPUCuN\|Y1PzNizszN	NXzhfm1CW0GQR1XS
DBTRG-05MG	NEmydItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILN[3ZKSzVyPUCuN\|gxPTRizszN	NET2cXBUSU6JRWK=
SK-MEL-24	NYqyfHN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnaZoNKSzVyPUCuN\|k4QTFizszN	NEjRXItUSU6JRWK=
8305C	M1jNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P6fmlEPTB;MD6zPVc6OyEQvF2=	MXTTRW5ITVJ?
OVCAR-4	M2GybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnleFBCUUN3ME2wMlQyPTh4IN88US=>	M3fPS3NCVkeHUh?=
HLE	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrtWZR[UUN3ME2wMlQyQDZizszN	NFSyeGNUSU6JRWK=
NCI-H747	NEXiOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwNEKxN\|ch\|ryP	MWDTRW5ITVJ?
SW780	NXG1cop2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ntUmlEPTB;MD60NlM1PiEQvF2=	M3;s[3NCVkeHUh?=
KYSE-150	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkniTWM2OD1yLkSyOFE2KM7:TR?=	NEXSU2RUSU6JRWK=
H4	M{X2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3hWFRKSzVyPUCuOFI1PTFizszN	NVLNW495W0GQR1XS
SW1088	NY\HSld5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwNESzPUDPxE1?	M3jDS3NCVkeHUh?=
SF268	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXDTWM2OD1yLkS0PFYh\|ryP	NXTueW1pW0GQR1XS
RT4	NGj2PHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHaTWM2OD1yLkS1NVEyKM7:TR?=	NX7XRVh4W0GQR1XS
NCI-H522	NWnGc3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwNEWyO{DPxE1?	M3XLS3NCVkeHUh?=
LCLC-97TM1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vIR2lEPTB;MD60OlE6PSEQvF2=	MnjoV2FPT0WU
CAL-39	M3zSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fRVGlEPTB;MD60OlUyQSEQvF2=	NICxZ2JUSU6JRWK=
CAL-120	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rNbmlEPTB;MD60O\|Y1OyEQvF2=	NHHSS\|NUSU6JRWK=
ESS-1	NFfwTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jzU2lEPTB;MD60O\|gzOSEQvF2=	M1zXNXNCVkeHUh?=
KARPAS-45	NV;BfIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED3cVJKSzVyPUCuOFg6OzNizszN	NEDDO4hUSU6JRWK=
DU-4475	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwNEm1NVEh\|ryP	NVy1NVVRW0GQR1XS
VMRC-RCZ	NYLqeHZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLYU\|FKSzVyPUCuOFk6ODRizszN	MmDEV2FPT0WU
HOS	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\0WZZKSzVyPUCuOVA{PjVizszN	MlrDV2FPT0WU
MOLT-16	M4T6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;3SFVKSzVyPUCuOVE5ODhizszN	MXPTRW5ITVJ?
RPMI-6666	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNUKxN\|Uh\|ryP	NELKPXZUSU6JRWK=
K052	NHvx[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1raSmlEPTB;MD61NlE1KM7:TR?=	M1HUN3NCVkeHUh?=
EHEB	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\kTWM2OD1yLkWyNVgzKM7:TR?=	NX\Pb3JUW0GQR1XS
MFH-ino	NFPEW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLjR5pKSzVyPUCuOVI{PTFizszN	M1TBRXNCVkeHUh?=
A4-Fuk	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTHTWM2OD1yLkWyOVI5KM7:TR?=	MmnLV2FPT0WU
SW1417	M4mwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwNUK3PFEh\|ryP	Mk\iV2FPT0WU
DoTc2-4510	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwNUS5OVgh\|ryP	NYnodIZwW0GQR1XS
TE-12	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvmeFI5UUN3ME2wMlU2PzN3IN88US=>	MlzoV2FPT0WU
8-MG-BA	NUG3N2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXyeFZsUUN3ME2wMlU3ODV4IN88US=>	NWrkSFhvW0GQR1XS
ECC12	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v4UGlEPTB;MD61OlU2QCEQvF2=	M1HDWXNCVkeHUh?=
CHL-1	NFTUTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwNUe0OlMh\|ryP	MmPCV2FPT0WU
LCLC-103H	NUfVUZdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwNUizOFQh\|ryP	MYPTRW5ITVJ?
OS-RC-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwNUizO\|kh\|ryP	Ml\kV2FPT0WU
RO82-W-1	NIC3fGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwNUm2NVUh\|ryP	MWHTRW5ITVJ?
A3-KAW	NHXmUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwNkG0Olch\|ryP	MmnHV2FPT0WU
NCCIT	NVzWTZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH5TWM2OD1yLk[xO\|E2KM7:TR?=	MXfTRW5ITVJ?
IST-SL2	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnXTWM2OD1yLk[yOVIzKM7:TR?=	NWfxNoxIW0GQR1XS
GI-ME-N	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\0TWM2OD1yLk[zNFY6KM7:TR?=	MV3TRW5ITVJ?
ES6	NF3TU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjnWGRuUUN3ME2wMlY{Ojl3IN88US=>	M1LRWHNCVkeHUh?=
BL-41	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwNkOzOVIh\|ryP	MXXTRW5ITVJ?
Ca-Ski	M3vXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjVbGhKSzVyPUCuOlQ5OSEQvF2=	MnvBV2FPT0WU
HOP-92	NXi3N4RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwNkW2O\|Ih\|ryP	MUTTRW5ITVJ?
SK-LMS-1	NU\j[lQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX70S3IyUUN3ME2wMlY3PDdizszN	NYr5PYg1W0GQR1XS
EW-13	NWfxbpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfYc3dTUUN3ME2wMlY3Pzd7IN88US=>	NVX4WlhkW0GQR1XS
647-V	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\mZWlEPTB;MD62PFE1QCEQvF2=	M1TBb3NCVkeHUh?=
JiyoyeP-2003	NGPzRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjrTHJKSzVyPUCuOlk4OzhizszN	M4nWXHNCVkeHUh?=
WSU-NHL	M4TmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPITWM2OD1yLkewPFg4KM7:TR?=	M3\T[XNCVkeHUh?=
U-698-M	M4[5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwN{GwOlMh\|ryP	NVnXbnFsW0GQR1XS
HC-1	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXDTWM2OD1yLkeyOFA2KM7:TR?=	MX\TRW5ITVJ?
8505C	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3mVmgxUUN3ME2wMlczPzRzIN88US=>	MUjTRW5ITVJ?
HUTU-80	M4rVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\6bnpKSzVyPUCuO\|M{PDlizszN	NVrxSYRPW0GQR1XS
LB1047-RCC	NFj2VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwN{O1N\|gh\|ryP	MkizV2FPT0WU
GAMG	NFTFO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwN{O2OVMh\|ryP	MofMV2FPT0WU
CAL-12T	NH\le2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu4TWM2OD1yLkezPFc4KM7:TR?=	M4qxbnNCVkeHUh?=
NCI-SNU-1	NIL4T4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFuxTGZKSzVyPUCuO\|czPzhizszN	MWXTRW5ITVJ?
HTC-C3	NV[yZoZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlyyTWM2OD1yLke3OFUyKM7:TR?=	M{TDWnNCVkeHUh?=
HPAF-II	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rZWWlEPTB;MD63O\|UxOSEQvF2=	NVPmPFg3W0GQR1XS
KGN	NW\FWoRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\ZWFFuUUN3ME2wMlc5ODhzIN88US=>	MYHTRW5ITVJ?
EFO-27	NXjxXnI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTHTWM2OD1yLke4O\|M{KM7:TR?=	NEDleXdUSU6JRWK=
MEL-HO	M2LQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTpTWM2OD1yLke5OFQ6KM7:TR?=	MWjTRW5ITVJ?
KYSE-270	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHUTHNiUUN3ME2wMlgxPTJ7IN88US=>	NXTCWIJiW0GQR1XS
NCI-H1755	NYj5cllxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rvdGlEPTB;MD64NFcyPCEQvF2=	M3nLZXNCVkeHUh?=
MFM-223	NHj2cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWj4T5J3UUN3ME2wMlgyPDB5IN88US=>	MYHTRW5ITVJ?
G-361	NUntN2FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHyTWM2OD1yLkixPFk4KM7:TR?=	MkHlV2FPT0WU
ETK-1	M33ESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHleGpKSzVyPUCuPFI1PDFizszN	MWnTRW5ITVJ?
LU-99A	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwOES3NFEh\|ryP	NYfqOpFSW0GQR1XS
IST-MEL1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET4eYlKSzVyPUCuPFU4OzJizszN	NI\y[YxUSU6JRWK=
L-540	NHu1U2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ntb2lEPTB;MD64OVgxOSEQvF2=	MofoV2FPT0WU
U-2-OS	M4TJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LUZWlEPTB;MD64OVg1PiEQvF2=	M4j5eHNCVkeHUh?=
HT-1376	NELvUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHFO2RKSzVyPUCuPFYxPTFizszN	NYnPcJU3W0GQR1XS
COLO-680N	NXfPVZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr0NHdGUUN3ME2wMlg4QTN\|IN88US=>	M1fHNnNCVkeHUh?=
NCI-H1581	NIrjZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwOEmyPVch\|ryP	MkP0V2FPT0WU
HuCCT1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\uT4VPUUN3ME2wMlg6PTR6IN88US=>	NFy3XoRUSU6JRWK=
BB30-HNC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwOUK0Olkh\|ryP	MWfTRW5ITVJ?
NCI-H2347	NY\0dJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XNW2lEPTB;MD65N\|I6OiEQvF2=	MYfTRW5ITVJ?
G-401	NWCwUGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwOUO2PVUh\|ryP	M17IOnNCVkeHUh?=
NCI-H358	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe4U\|ZKSzVyPUCuPVUxOTRizszN	NFHpbWpUSU6JRWK=
HCC1395	NWrvT3l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnSdJZ6UUN3ME2wMlk2PDZzIN88US=>	NE\z[XlUSU6JRWK=
J82	M3fIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwOUW1OFMh\|ryP	NWrlc4NNW0GQR1XS
KE-37	NHywWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly3TWM2OD1yLkm2N\|g4KM7:TR?=	NVHmSHl4W0GQR1XS
NOMO-1	NIPrZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr5R21KSzVyPUCuPVY2PjRizszN	Ml7UV2FPT0WU
ML-2	NXXpOZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\vfpY5UUN3ME2wMlk6PzVizszN	NEW1S2ZUSU6JRWK=
SW872	M3O0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUK1NIkxUUN3ME2wMlk6Pzd3IN88US=>	MWLTRW5ITVJ?
KYSE-520	NFrJN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFwMEC0PVQh\|ryP	MkOyV2FPT0WU
HL-60	M{XXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL3TWM2OD1zLkCwPVch\|ryP	Mne4V2FPT0WU
HDLM-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fTRmlEPTB;MT6wNVI2OiEQvF2=	NUfwVI9IW0GQR1XS
MIA-PaCa-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFwMEGzO\|Uh\|ryP	NFjWfoJUSU6JRWK=
TCCSUP	M{nvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwMEG3N\|Ih\|ryP	MYDTRW5ITVJ?
SH-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTYfWlKSzVyPUGuNFIzPDRizszN	M3rjTHNCVkeHUh?=
MG-63	M3HiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7XZWpYUUN3ME2xMlAzPjF4IN88US=>	NFjlO3hUSU6JRWK=
NB6	NW\DVoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH2VGFmUUN3ME2xMlA{OTB7IN88US=>	NUDKcVlDW0GQR1XS
CAL-54	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTFwMEO5OVkh\|ryP	M33Bb3NCVkeHUh?=
DU-145	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTFwMEiwO\|Mh\|ryP	MUPTRW5ITVJ?
HCE-4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLPTWM2OD1zLkC5Nlg3KM7:TR?=	Mkf1V2FPT0WU
U-266	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonUTWM2OD1zLkC5OlM{KM7:TR?=	MnfNV2FPT0WU
HT-1197	NUHPNHZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfE[nFqUUN3ME2xMlEyPDN6IN88US=>	NIPFUpFUSU6JRWK=
EW-1	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXnTWM2OD1zLkG0NVI5KM7:TR?=	MV\TRW5ITVJ?
MHH-NB-11	M1rW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H5W2lEPTB;MT6xOVM3QCEQvF2=	MmfrV2FPT0WU
NCI-H2405	NIfvb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DpemlEPTB;MT6xOlE3KM7:TR?=	MYHTRW5ITVJ?
COLO-668	NWfZdZUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XLeGlEPTB;MT6xOlQ6KM7:TR?=	MXXTRW5ITVJ?
IMR-5	MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPTW4ZKSzVyPUGuNVY6OzZizszN	MmXFV2FPT0WU
ARH-77	M{XPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3SXm5XUUN3ME2xMlIzQTJ2IN88US=>	MUDTRW5ITVJ?
BHT-101	M4OwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTFwMkO0PUDPxE1?	NVftTpJ7W0GQR1XS
SCC-25	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTFwMkO1N\|Yh\|ryP	MlvSV2FPT0WU
NTERA-S-cl-D1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2qzNmlEPTB;MT6yOFM1PiEQvF2=	MljFV2FPT0WU
MKN28	M4OzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH2RY9KSzVyPUGuNlU3OzZizszN	MnTiV2FPT0WU
KS-1	NUXjRXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTFwMkiyOlkh\|ryP	NG\1SFdUSU6JRWK=
NCI-H1734	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;mTWM2OD1zLkK4PVE{KM7:TR?=	NFy0TJlUSU6JRWK=
ES7	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XWTmlEPTB;MT6yPVU1OiEQvF2=	MoXuV2FPT0WU
NCI-H838	M3zPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvBTWM2OD1zLkOwOlE2KM7:TR?=	NHLOd3FUSU6JRWK=
HEC-1	M2ruVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPoVpJKSzVyPUGuN\|M4PTVizszN	NFmxeGJUSU6JRWK=
ME-180	NHrXTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTRTWM2OD1zLkO3PVk{KM7:TR?=	M4fjfnNCVkeHUh?=
MMAC-SF	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvNNlh4UUN3ME2xMlM6PTl3IN88US=>	Mm[zV2FPT0WU
IA-LM	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLPTm5KSzVyPUGuOFA6OTRizszN	MmfuV2FPT0WU
MN-60	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFmxclZKSzVyPUGuOFMyOTRizszN	MXXTRW5ITVJ?
SIMA	NYW0[G42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrh[3dKSzVyPUGuOFg3QDdizszN	M3rqUXNCVkeHUh?=
NCI-H1770	NX;zVG43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXETWM2OD1zLkWyNFU1KM7:TR?=	M1LRPXNCVkeHUh?=
ONS-76	M4Hie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi2TWM2OD1zLkWyN\|EyKM7:TR?=	M4HuNXNCVkeHUh?=
LB771-HNC	MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjiTGJvUUN3ME2xMlU{QTB4IN88US=>	M3zKZXNCVkeHUh?=
SW48	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwNUSyOFMh\|ryP	NGO2bnJUSU6JRWK=
KYSE-140	NFSxd\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[2W2lEPTB;MT61OVc1OSEQvF2=	MVTTRW5ITVJ?
SW626	NF;OPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHKTVdKSzVyPUGuOVgyPiEQvF2=	NFr4dG5USU6JRWK=
MC-CAR	M2fWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHJTWM2OD1zLkW4OlY{KM7:TR?=	MWrTRW5ITVJ?
D-336MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zadGlEPTB;MT62Nlk1KM7:TR?=	Mni4V2FPT0WU
SK-MEL-3	NGjiSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD6TWM2OD1zLk[zPVAzKM7:TR?=	MUTTRW5ITVJ?
MHH-PREB-1	NILrTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q3[GlEPTB;MT62OFQ4OyEQvF2=	NWfsO4ZvW0GQR1XS
Calu-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHke3JKSzVyPUGuOlU{QDZizszN	NFfHNpdUSU6JRWK=
HCC1806	NXnVbpBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS0TZNvUUN3ME2xMlY3PjFzIN88US=>	MkHtV2FPT0WU
A101D	NELGOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XoUGlEPTB;MT62Olc5OSEQvF2=	MmrlV2FPT0WU
A704	M{Hob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn4N2ZKSzVyPUGuOlg{OTFizszN	MnLFV2FPT0WU
LB831-BLC	M3myZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;mU2lEPTB;MT62PVg2PCEQvF2=	M{KwSHNCVkeHUh?=
RL95-2	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TGemlEPTB;MT63NVQ3OyEQvF2=	MYTTRW5ITVJ?
RPMI-2650	NFHhfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkntTWM2OD1zLkeyO\|E6KM7:TR?=	NWTDfYpKW0GQR1XS
NH-12	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTFwN{O0Nlch\|ryP	M2XH[XNCVkeHUh?=
AGS	M3LIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHYTWM2OD1zLke2N\|U5KM7:TR?=	MWfTRW5ITVJ?
NEC8	M2n1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFwN{i5PVUh\|ryP	MWHTRW5ITVJ?
NCI-H2009	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTFwN{m3NlEh\|ryP	MlPYV2FPT0WU
A498	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vxeGlEPTB;MT64NVI5OiEQvF2=	MYnTRW5ITVJ?
NCI-H810	NGjCZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX0T\|NKSzVyPUGuPFE3ODZizszN	M3X5NXNCVkeHUh?=
SK-NEP-1	M{LBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrFTWM2OD1zLkizO\|Y4KM7:TR?=	NVjI[Fk4W0GQR1XS
D-542MG	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTGdYZKSzVyPUGuPFU5PTFizszN	NFr0RmVUSU6JRWK=
KNS-42	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTFwOE[yOlYh\|ryP	NULrPZFYW0GQR1XS
NCI-H2452	M1Pke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTFwOEmwO\|Qh\|ryP	NVz2TYdUW0GQR1XS
SK-MEL-2	MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvlWmZKSzVyPUGuPVAzPzFizszN	NWDBT3BGW0GQR1XS
OVCAR-5	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XTSmlEPTB;MT65NFY4PSEQvF2=	NE\ZR5RUSU6JRWK=
SNG-M	NGnhbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmW4TWM2OD1zLkm1PFU5KM7:TR?=	NVzq[3pjW0GQR1XS
A673	NWfH[JJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vhdGlEPTB;MT65O\|UyPiEQvF2=	MX3TRW5ITVJ?
L-428	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFK0bY5KSzVyPUGuPVkyPzlizszN	MVPTRW5ITVJ?
KM-H2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:zW3VKSzVyPUKuNFExQSEQvF2=	MXXTRW5ITVJ?
MC-IXC	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTJwMEKyO\|Mh\|ryP	M1\rTnNCVkeHUh?=
COLO-678	NInjU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnBTWM2OD1{LkC0NlA4KM7:TR?=	NYC0S5hYW0GQR1XS
MEL-JUSO	NXfNNnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjubWxKSzVyPUKuNFc5PTFizszN	NV2z[nBwW0GQR1XS
HCC38	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTJwMEi0N\|Mh\|ryP	M1K0NHNCVkeHUh?=
UACC-62	NEPKXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HMdWlEPTB;Mj6wPFg2PSEQvF2=	MVjTRW5ITVJ?
OAW-42	M4\pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWewNlE4UUN3ME2yMlA6PzFzIN88US=>	MmX3V2FPT0WU
LB996-RCC	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzRS4N7UUN3ME2yMlE{QDF5IN88US=>	M2PzV3NCVkeHUh?=
COR-L105	M4K0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PSUWlEPTB;Mj6xOlM4OyEQvF2=	NE\hc3RUSU6JRWK=
RCC10RGB	NEDwcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWWyVZgxUUN3ME2yMlE5PTd4IN88US=>	NV3wNIhFW0GQR1XS
A431	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYH0T2V2UUN3ME2yMlE6ODF7IN88US=>	NWHIRm1mW0GQR1XS
NCI-H292	NVX0[2ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3RW2hKSzVyPUKuNlM6PTFizszN	NVzNNGNMW0GQR1XS
SK-UT-1	NUPTT4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJwM{OxPFQh\|ryP	NIG5cHBUSU6JRWK=
PANC-08-13	NHPGU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmWyTWM2OD1{LkOzNlM2KM7:TR?=	NVzicZp5W0GQR1XS
ST486	NGOxd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Lye2lEPTB;Mj60NVA1QCEQvF2=	MnvDV2FPT0WU
SJSA-1	M4PwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13kWGlEPTB;Mj60NVI4OSEQvF2=	NF;4d3NUSU6JRWK=
RKO	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jH[mlEPTB;Mj60NlAzQSEQvF2=	NUfYOZFwW0GQR1XS
NCI-H1793	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LRfGlEPTB;Mj60OFAzQSEQvF2=	MmPZV2FPT0WU
639-V	M3z5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTJwNEWzPFIh\|ryP	NVX2cZV5W0GQR1XS
ES3	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LmUWlEPTB;Mj60PVc{PyEQvF2=	MnXUV2FPT0WU
NCI-H1792	NXzNVmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\KeWlEPTB;Mj61OlgzPiEQvF2=	NGP5SY1USU6JRWK=
NCI-H1651	NHz1TZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLseIJ7UUN3ME2yMlU5OjFizszN	M2e1enNCVkeHUh?=
SN12C	NXTMW4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3ZTWM2OD1{LkW4OFg4KM7:TR?=	M{fmbHNCVkeHUh?=
COLO-679	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HWSGlEPTB;Mj61PFYxPSEQvF2=	NGXEZVJUSU6JRWK=
U-118-MG	NUjUfJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvnO283UUN3ME2yMlU5QDd{IN88US=>	MXXTRW5ITVJ?
Ramos-2G6-4C10	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnkdmo2UUN3ME2yMlY1QDB5IN88US=>	M2P1UXNCVkeHUh?=
HCT-15	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH35SndKSzVyPUKuOlg4QTJizszN	NGr4[YFUSU6JRWK=
MDA-MB-157	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW4TlFKSzVyPUKuO\|A4PDdizszN	NE\5S2lUSU6JRWK=
K5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fWUWlEPTB;Mj63NVg1PSEQvF2=	MmrxV2FPT0WU
MKN45	M{HKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTJwN{OzOlYh\|ryP	NUH6[ZpxW0GQR1XS
DMS-273	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTLTWM2OD1{Lke1OlMzKM7:TR?=	Mki0V2FPT0WU
C8166	M3TS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nRR2lEPTB;Mj63PFUyOyEQvF2=	MkjwV2FPT0WU
Calu-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTSc2lxUUN3ME2yMlc5QTZ7IN88US=>	NIq0U3RUSU6JRWK=
SNB75	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzkTIxjUUN3ME2yMlg5PTN3IN88US=>	Mm\RV2FPT0WU
BFTC-905	NW[2bVJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTxTWM2OD1{LkmwNVkyKM7:TR?=	NH\QV\|JUSU6JRWK=
C-4-II	M3PZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXJeFVKSzVyPUKuPVE{PTNizszN	MXHTRW5ITVJ?
MS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPVTWM2OD1{Lkm2O\|Y6KM7:TR?=	MnLEV2FPT0WU
A375	M17Pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3juOGlEPTB;Mz6wPFE5PCEQvF2=	NIjn[2JUSU6JRWK=
KYSE-70	NY\JTW86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvlTWM2OD1\|LkC4PFgzKM7:TR?=	NWjFT3JFW0GQR1XS
KYSE-510	NVm3WHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL6b49jUUN3ME2zMlExQTl3IN88US=>	NVTpNIJoW0GQR1XS
LN-405	NFPaPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki3TWM2OD1\|LkGzOVE5KM7:TR?=	MYnTRW5ITVJ?
BOKU	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXlWox4UUN3ME2zMlE1OjV4IN88US=>	M2jXNXNCVkeHUh?=
TE-10	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUL3OZNbUUN3ME2zMlE4OzZ{IN88US=>	NIW2PVJUSU6JRWK=
MKN1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHlSYlqUUN3ME2zMlE5PDh\|IN88US=>	MlrJV2FPT0WU
M059J	NGfGcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrO[HNKSzVyPUOuNlAyPzNizszN	NYL5bHpIW0GQR1XS
GOTO	NHG0bIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fkNmlEPTB;Mz6yNlA{QSEQvF2=	M2j1VnNCVkeHUh?=
DK-MG	M2HRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfPTWM2OD1\|LkK1PVc3KM7:TR?=	NEDhW2tUSU6JRWK=
NCI-H727	NXjjd5pMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDHTWM2OD1\|LkK2OVgh\|ryP	MmXLV2FPT0WU
NB12	NFvwZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfDTnFGUUN3ME2zMlM{OjJ2IN88US=>	M1\4[XNCVkeHUh?=
DOK	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3u0[mlEPTB;Mz6zOlE5PiEQvF2=	NXTqXmN4W0GQR1XS
KYSE-410	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\mTWM2OD1\|LkO2Nlg4KM7:TR?=	NYW0XFl2W0GQR1XS
AM-38	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH1TWM2OD1\|LkO4NFUyKM7:TR?=	M1jCZXNCVkeHUh?=
GR-ST	NGrGTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPiXWpKSzVyPUOuOFU4OzJizszN	MUTTRW5ITVJ?
D-247MG	NXXqR5RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVmzO4hbUUN3ME2zMlQ5OjZ\|IN88US=>	NEnvPXNUSU6JRWK=
TE-8	M3:3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\hfGlEPTB;Mz60PVM{OyEQvF2=	M{DzNXNCVkeHUh?=
LS-411N	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXZTWM2OD1\|LkS5OlkzKM7:TR?=	M{SxZnNCVkeHUh?=
SK-MES-1	NFXmWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrVPIo4UUN3ME2zMlU3PDN\|IN88US=>	NXj1NoFWW0GQR1XS
SF295	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTNwNkG1OVIh\|ryP	MmPsV2FPT0WU
SK-MEL-30	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTNwNkW5NlEh\|ryP	Mnj0V2FPT0WU
LB2241-RCC	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DFcWlEPTB;Mz62OlI3KM7:TR?=	MXjTRW5ITVJ?
PC-14	NHqwSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTNwNk[0N\|ch\|ryP	MljSV2FPT0WU
EW-7	NWfSNJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLaTWM2OD1\|Lk[3Olk{KM7:TR?=	NW\4O2xiW0GQR1XS
NMC-G1	NFrrVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\TTWM2OD1\|LkexPFM4KM7:TR?=	MWXTRW5ITVJ?
TE-441-T	NG\lepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3sO5JKSzVyPUOuO\|MxOjhizszN	NFnXW\|BUSU6JRWK=
NCI-H1618	M2HzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVz1UVFzUUN3ME2zMlgyQDd3IN88US=>	NVHUbIt5W0GQR1XS
PANC-03-27	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjZTWM2OD1\|LkixPVE3KM7:TR?=	MUPTRW5ITVJ?
NCI-H2228	NIPzbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvOUmpKSzVyPUOuPFMyOjZizszN	MYfTRW5ITVJ?
CAPAN-1	NYTaXFQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTNwOEewNFkh\|ryP	M1vrcXNCVkeHUh?=
KLE	M3f5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTNwOUC2O{DPxE1?	MX3TRW5ITVJ?
Becker	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXoTWM2OD1\|LkmyPFQ6KM7:TR?=	MXnTRW5ITVJ?
SK-PN-DW	M3rDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X0OWlEPTB;ND6wO\|k4PCEQvF2=	NH7vTmtUSU6JRWK=
Hs-578-T	NFzkOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn6TWM2OD12LkC4N\|A3KM7:TR?=	NVfVbVVoW0GQR1XS
RS4-11	NGPBUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfHTWM2OD12LkGxNlU2KM7:TR?=	M130OnNCVkeHUh?=
D-502MG	M1j4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvoNm1KSzVyPUSuNVY6QTdizszN	M4foTXNCVkeHUh?=
GI-1	NIXRZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfZPG5KSzVyPUSuNlgzQTlizszN	NHOwfFlUSU6JRWK=
NCI-H209	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTuR2ZrUUN3ME20MlM{PzhizszN	NVmwWJFFW0GQR1XS
SK-OV-3	NWXaS5NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jkXWlEPTB;ND60PFE1QSEQvF2=	MlT3V2FPT0WU
LOUCY	M1;QSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4e4PGlEPTB;ND60PFQ{OiEQvF2=	Ml\iV2FPT0WU
NCI-H69	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mny3TWM2OD12LkWxO\|k{KM7:TR?=	M4O2WnNCVkeHUh?=
SCC-9	NGPSfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHy1N\|JKSzVyPUSuOVMyPzJizszN	MoHlV2FPT0WU
NCI-H526	NEjuOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;RO2lEPTB;ND61PVI6OyEQvF2=	NGryXWRUSU6JRWK=
NCI-H2170	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzETWM2OD12Lk[2O\|cyKM7:TR?=	MmTKV2FPT0WU
SR	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHSWZFnUUN3ME20MlcxODR6IN88US=>	M2fzW3NCVkeHUh?=
CMK	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnRO3o1UUN3ME20MlczOTBzIN88US=>	NXL4fYtVW0GQR1XS
COLO-829	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXybG53UUN3ME20Mlc4ODR\|IN88US=>	NVvJR5UyW0GQR1XS
HuO-3N1	MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfBTWM2OD12LkizNlgyKM7:TR?=	MnS4V2FPT0WU
5637	M2H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTRwOUC0PFch\|ryP	NVrKOm5IW0GQR1XS
A253	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D4NWlEPTB;ND65O\|cxQCEQvF2=	MkXmV2FPT0WU
NB10	NHW0Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjRZlFKSzVyPUWuNFc1QTdizszN	MYPTRW5ITVJ?
SF539	M1nuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvXWWpKSzVyPUWuNFk6PTlizszN	NVTwfItQW0GQR1XS
HAL-01	M2jGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H1bmlEPTB;NT6xOFY1PSEQvF2=	NWL3UYhDW0GQR1XS
MHH-ES-1	M2X0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nYS2lEPTB;NT6xOlkzPSEQvF2=	NYfRfnFSW0GQR1XS
DEL	M2H1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUixbW5DUUN3ME21MlI4PTh{IN88US=>	MVjTRW5ITVJ?
NCI-H1299	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGixR2pKSzVyPUWuN\|UxODdizszN	Mn7MV2FPT0WU
ChaGo-K-1	NYLLd4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DKfGlEPTB;NT6zOVExPyEQvF2=	NXnmRWprW0GQR1XS
HMV-II	NVP5[YR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7tTWM2OD13LkO5OFMh\|ryP	NYH1[m4xW0GQR1XS
NB69	M1nOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYK2NYxRUUN3ME21MlM6PjNzIN88US=>	NXPFepc4W0GQR1XS
NCI-H1882	MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHITWM2OD13LkSzN\|Y1KM7:TR?=	MVzTRW5ITVJ?
SNU-475	M1q0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO5bpZKSzVyPUWuOFcyPzFizszN	M3XwUXNCVkeHUh?=
RXF393	NWn3fmZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrWPIVNUUN3ME21MlQ5PDl2IN88US=>	NF;sXZRUSU6JRWK=
CAL-51	M3nTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXqycYZtUUN3ME21MlYzQDV\|IN88US=>	MY\TRW5ITVJ?
SW1573	NVLJSpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfFTWM2OD13Lk[zOVM1KM7:TR?=	NXKwUY5iW0GQR1XS
GCT	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\oTWM2OD13Lke1PVI6KM7:TR?=	MlTWV2FPT0WU
COR-L88	NVvQdFhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXHcndKSzVyPUWuO\|Y5PDZizszN	M2jJV3NCVkeHUh?=
MDA-MB-134-VI	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TPXmlEPTB;NT64O\|U{PiEQvF2=	NXrhcmR5W0GQR1XS
NB5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnsS3JoUUN3ME21MlkzPDRizszN	MVnTRW5ITVJ?
GMS-10	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXQNXBKSzVyPUWuPVY5PjFizszN	MkfLV2FPT0WU
CHP-212	MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO1SHZKUUN3ME22MlQ5OjZ5IN88US=>	MYfTRW5ITVJ?
TE-11	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTZwNUWxPFIh\|ryP	Mlu3V2FPT0WU
SW962	NI\3NG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHKPHZ2UUN3ME22MlY2Pzd2IN88US=>	M4X2e3NCVkeHUh?=
MZ2-MEL	NFTTTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGH0VI9KSzVyPU[uPFIxOTFizszN	NELwUFlUSU6JRWK=
C-33-A	NFfWVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjXTWM2OD14LkmxOlg5KM7:TR?=	M33UfnNCVkeHUh?=
IGR-1	NFrrfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTZwOUe4NlYh\|ryP	Ml[2V2FPT0WU
MOLT-4	NILRO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;kTWM2OD15LkG1OFA3KM7:TR?=	NHzGc3BUSU6JRWK=
NCI-H1650	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXqTWM2OD15LkK3NFQ3KM7:TR?=	MlvvV2FPT0WU
AsPC-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTdwMki2NFUh\|ryP	NFfjV5ZUSU6JRWK=
SNU-C2B	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTdwMkm1O\|Eh\|ryP	Mm\YV2FPT0WU
MKN7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTdwM{eyN\|Uh\|ryP	M1;aSnNCVkeHUh?=
SW620	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXpZWVKSzVyPUeuN\|gzODVizszN	NIfGWZdUSU6JRWK=
SK-MEL-28	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;DTWM2OD15LkSwO\|k5KM7:TR?=	NX\wd3FrW0GQR1XS
TE-6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHqx[3VKSzVyPUeuOFQ6ODhizszN	Moq5V2FPT0WU
D-263MG	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LhTWlEPTB;Nz60OVc3OiEQvF2=	MnvGV2FPT0WU
NCI-H1355	NYLJUVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rTWGlEPTB;Nz63O\|AzQSEQvF2=	MUHTRW5ITVJ?
DSH1	M1Ho[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELCOmpKSzVyPUeuO\|k4PjJizszN	NH2xZnFUSU6JRWK=
NCI-H460	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPDV\|RKSzVyPUiuNFA3QTRizszN	MnuwV2FPT0WU
NCI-H1563	M3TZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\ubXQyUUN3ME24MlA4PTB6IN88US=>	NXrNeZBEW0GQR1XS
SW948	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnS5TWM2OD16LkGwO\|Q1KM7:TR?=	MWjTRW5ITVJ?
LK-2	NELYfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRThwMUK4N\|Mh\|ryP	M33sOnNCVkeHUh?=
HT-1080	M1vkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjHS5pKSzVyPUiuNVMyPzVizszN	M4\Gd3NCVkeHUh?=
NCI-H441	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDmTFN7UUN3ME24MlE6OyEQvF2=	MnvjV2FPT0WU
HSC-4	NVzPbVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHTTWM2OD16LkK4O\|Ih\|ryP	NX3a[oc1W0GQR1XS
LXF-289	NE\1ZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIq4S5BKSzVyPUiuN\|U6PDNizszN	MV;TRW5ITVJ?
MRK-nu-1	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q2UWlEPTB;OD6zOlMxPCEQvF2=	NHrZPIdUSU6JRWK=
no-11	NGW2UHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\GVo5XUUN3ME24MlQ4OTN\|IN88US=>	M3zOZXNCVkeHUh?=
SNU-387	MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\GRXVKSzVyPUiuOlMzPDZizszN	MW\TRW5ITVJ?
Detroit562	NV3uT2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTBPGFKSzVyPUiuO\|U1PTVizszN	NVPjWFc2W0GQR1XS
SW954	NUTPcVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDOTWM2OD16Lke2PFMzKM7:TR?=	MV3TRW5ITVJ?
P12-ICHIKAWA	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:yOIpKSzVyPUiuO\|g6PCEQvF2=	NYn1b2d4W0GQR1XS
TE-9	M1[1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRThwOEGwOlIh\|ryP	NGjDRXJUSU6JRWK=
NB13	NXvWeVk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRThwOEO3PVYh\|ryP	NIHWWGNUSU6JRWK=
BPH-1	NXXadIZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRThwOEWwPFEh\|ryP	NHO1fVZUSU6JRWK=
KMOE-2	NVu4bJZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj2PXlKSzVyPUiuPFc5QTJizszN	MmT1V2FPT0WU
RPMI-8402	NF\OeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XjUWlEPTB;OD64PVkzPiEQvF2=	NF22W4RUSU6JRWK=
OVCAR-3	M4LQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LhW2lEPTB;OD65O\|c{OiEQvF2=	NFjwfWtUSU6JRWK=
NCI-H2196	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HXfWlEPTB;OD65PFYxPiEQvF2=	NIDuXJZUSU6JRWK=
MZ7-mel	NXjaVGM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[5OphKSzVyPUmuNFM1PiEQvF2=	MkXEV2FPT0WU
GP5d	NVnwc\|ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLidJgzUUN3ME25MlA3OzF\|IN88US=>	NEfPO2RUSU6JRWK=
NCI-N87	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fQPGlEPTB;OT60OFc{OSEQvF2=	MXLTRW5ITVJ?
EW-16	M1TORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYn5V40xUUN3ME25MlQ1QDR6IN88US=>	NYD3[HZJW0GQR1XS
Calu-6	NXj1clhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTlwNEm3NFMh\|ryP	Moq2V2FPT0WU
LC4-1	NWK0NXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXziTo1{UUN3ME25MlYzPTdizszN	M{i5N3NCVkeHUh?=
CCRF-CEM	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITTfnZKSzVyPUmuOlg4PjZizszN	MnvNV2FPT0WU
BC-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTsSGhoUUN3ME25Mlc5QTlizszN	MoHwV2FPT0WU
NCI-SNU-16	NU\kT2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;qdo5YUUN3ME25Mlc6PDl3IN88US=>	MWDTRW5ITVJ?
NCI-H28	M4HTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LpOWlEPTB;OT64OFk{OyEQvF2=	MXLTRW5ITVJ?
SBC-1	NGm0WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTFyLkC3NkDPxE1?	M2exbHNCVkeHUh?=
TUR	NYfveY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTFyLkG2OVch\|ryP	MoDXV2FPT0WU
MDA-MB-231	NIHmNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r3UWlEPTB;MUCuNlEyPCEQvF2=	MYDTRW5ITVJ?
C3A	M2rIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXXd4ZKSzVyPUGwMlMyPzlizszN	M3z0UHNCVkeHUh?=
SW1990	M1\Nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;rU2lEPTB;MUCuN\|I5KM7:TR?=	MmTYV2FPT0WU
NCI-H1993	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrkNlRKSzVyPUGwMlU3QTNizszN	NYW4O3dCW0GQR1XS
SK-CO-1	M3f5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;vTWM2OD1zMD63O\|ch\|ryP	MkjvV2FPT0WU
OAW-28	MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX6THBQUUN3ME2xNE46QDh6IN88US=>	NYTSUI1bW0GQR1XS
HN	M2fCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Tjd2lEPTB;MUGuNVE{OSEQvF2=	M4P4cnNCVkeHUh?=
NCI-H1304	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXZTWM2OD1zMT6xOVc3KM7:TR?=	M{HHTHNCVkeHUh?=
Daoy	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFzLkSzN\|Yh\|ryP	MWHTRW5ITVJ?
VA-ES-BJ	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrTdIpKSzVyPUGxMlcyQTVizszN	NFzMXmZUSU6JRWK=
MCF7	NXi2enI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTFzLkixNlYh\|ryP	NVjlN203W0GQR1XS
VM-CUB-1	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFzLkmwPVEh\|ryP	NHm4WIpUSU6JRWK=
IPC-298	NUX5OVNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzIenlsUUN3ME2xNU46Ozh\|IN88US=>	NF;NS\|VUSU6JRWK=
NCI-H2126	M{O3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUiwdIhCUUN3ME2xNk4xOjF6IN88US=>	M{fCb3NCVkeHUh?=
OVCAR-8	NXfic\|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LmR2lEPTB;MUKuNVE1OSEQvF2=	MnzTV2FPT0WU
SJRH30	NUi5SHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\afFVKSzVyPUGyMlIzQTlizszN	M2T0XHNCVkeHUh?=
DMS-53	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nufGlEPTB;MUKuNlY1QSEQvF2=	M1zWOXNCVkeHUh?=
NCI-H322M	M13O[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnPNYl{UUN3ME2xNk4{OzV5IN88US=>	NHrlZ4hUSU6JRWK=
RVH-421	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTF{LkS5NFQh\|ryP	MnzKV2FPT0WU
Raji	NULvfG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTF{Lk[xOEDPxE1?	MoH3V2FPT0WU
MDA-MB-415	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVOwZ4ZSUUN3ME2xNk43PDR2IN88US=>	M3zERnNCVkeHUh?=
EFE-184	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfCeGZKSzVyPUGyMlcyODZizszN	NETySVBUSU6JRWK=
BFTC-909	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvpSYZKSzVyPUGyMlkzPDdizszN	NGnBbmNUSU6JRWK=
BHY	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkThTWM2OD1zMz6zN\|kh\|ryP	MkX2V2FPT0WU
YKG-1	NVH6S5hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HKemlEPTB;MUOuN\|c1QSEQvF2=	MoHrV2FPT0WU
EW-3	NFPNbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHtTWM2OD1zMz63NVY{KM7:TR?=	NFHTVVhUSU6JRWK=
HCC1143	NHzqR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXrTWM2OD1zMz63OFM4KM7:TR?=	NEnhN5hUSU6JRWK=
REH	NYD5V41bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3W0XGlEPTB;MUOuPFk5OiEQvF2=	MVTTRW5ITVJ?
CESS	NXr4d2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTF\|Lkm0PFkh\|ryP	NUXRS5I6W0GQR1XS
EFM-19	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;kOGlEPTB;MUSuNVEyOiEQvF2=	M1HZcnNCVkeHUh?=
U031	M{T0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTF2LkSwPFUh\|ryP	NYT2W4pPW0GQR1XS
ES1	M{TLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3sTWM2OD1zND60PFUyKM7:TR?=	M4nr[3NCVkeHUh?=
HSC-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTF2Lk[yNVUh\|ryP	MnTWV2FPT0WU
LOXIMVI	NXH5W2NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DyfGlEPTB;MUSuO\|A3QCEQvF2=	NIHFZ41USU6JRWK=
A388	M4jYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjkNYtyUUN3ME2xOE44PTV4IN88US=>	NILsZpVUSU6JRWK=
KP-N-YS	NF7KNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvmfYdFUUN3ME2xOE44PzNizszN	MV3TRW5ITVJ?
Capan-2	NF;FWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mny4TWM2OD1zND63PFYh\|ryP	NV7OXJZ5W0GQR1XS
SKG-IIIa	M2nw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[zbmlEPTB;MUSuPFg3OiEQvF2=	M1TVdXNCVkeHUh?=
HEL	NY\oXGVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3ITWM2OD1zND64PVk4KM7:TR?=	M1zqdHNCVkeHUh?=
BEN	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\oTWM2OD1zND65O\|Y3KM7:TR?=	NXTMVJU3W0GQR1XS
MC116	NFXRN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlGzTWM2OD1zNT6xOVk6KM7:TR?=	NVHLWphNW0GQR1XS
IGROV-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDzTWM2OD1zNT6yN\|E4KM7:TR?=	M4ryRXNCVkeHUh?=
NCI-H1648	M3j0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDsTWM2OD1zNT61N\|A2KM7:TR?=	MWfTRW5ITVJ?
ABC-1	NY\HUGEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF3LkiwN\|Mh\|ryP	MVHTRW5ITVJ?
EW-18	NX20eotyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3LTWM2OD1zNT65PVc6KM7:TR?=	M1[4SnNCVkeHUh?=
BC-3	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTF4LkC1OlIh\|ryP	NFvQbJJUSU6JRWK=
NCI-H1437	NFqyR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDjNlBKSzVyPUG2MlA3PjdizszN	NFTZemZUSU6JRWK=
SCC-15	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPOfmtKUUN3ME2xOk4zQDJ3IN88US=>	MVrTRW5ITVJ?
TT	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULyVHUyUUN3ME2xOk42QDh6IN88US=>	MmDwV2FPT0WU
KINGS-1	M3vlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHvTWM2OD1zNj64Nlc{KM7:TR?=	MkPoV2FPT0WU
C32	NYLJ[VRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nMXmlEPTB;MU[uPVcyPyEQvF2=	MljFV2FPT0WU
SBC-5	NGrIZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPaTWM2OD1zNz6xOFc6KM7:TR?=	NXnwSIhwW0GQR1XS
NB1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHne4VKSzVyPUG3MlMyQDhizszN	M3PsV3NCVkeHUh?=
EB-3	NF6xTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTF5LkW3OkDPxE1?	NGD1fmxUSU6JRWK=
NCI-H748	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkD1TWM2OD1zNz63NFM2KM7:TR?=	NIjkU3ZUSU6JRWK=
IST-SL1	M4W5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTF5Lke1NlYh\|ryP	NUPqSYx7W0GQR1XS
WM-115	M1vEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\FdpVKSzVyPUG3MlgxQDVizszN	NG\UfJVUSU6JRWK=
NCI-H226	NFXZRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF5Lkm1OFYh\|ryP	MlvBV2FPT0WU
CAL-33	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3aboRKUUN3ME2xPE4zPzhzIN88US=>	MVvTRW5ITVJ?
SCC-4	NV7SeWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF6LkOyNlkh\|ryP	NXvZfZZNW0GQR1XS
RMG-I	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDFTWM2OD1zOD62PVQ4KM7:TR?=	Mlf4V2FPT0WU
KOSC-2	NYrrV4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7IdpB6UUN3ME2xPE44PzR4IN88US=>	NYnMcFNkW0GQR1XS
A2058	Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTF6LkiyOVUh\|ryP	NXTzR5pOW0GQR1XS
HCC70	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnCToxiUUN3ME2xPU4{QDl2IN88US=>	NFXmPY1USU6JRWK=
C2BBe1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnTNWtKSzVyPUG5MlQyPDhizszN	MkLyV2FPT0WU
NCI-H650	NELkR\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz2bGxKSzVyPUG5MlU5QTlizszN	MmC2V2FPT0WU
CAL-72	NGrKUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTDZYNnUUN3ME2xPU43PzN5IN88US=>	NGHXZ41USU6JRWK=
L-363	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLZRVdKSzVyPUKwMlAzOTJizszN	M{PPVnNCVkeHUh?=
SNU-423	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfHeZhKSzVyPUKwMlExPDNizszN	MkfXV2FPT0WU
PLC-PRF-5	NUDnV\|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJyLkO5NFYh\|ryP	NGPXeWhUSU6JRWK=
SW1463	NFvmWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XEfmlEPTB;MkCuOFUzPSEQvF2=	M{\jOXNCVkeHUh?=
769-P	M3LhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJyLk[3Olkh\|ryP	M2D1PXNCVkeHUh?=
DMS-79	M3zhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTJyLki0PUDPxE1?	NEfKVYVUSU6JRWK=
Saos-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\BcY5CUUN3ME2yNE46PTV4IN88US=>	NWnmdFhxW0GQR1XS
CHP-126	NEPFbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJzLkS0OlIh\|ryP	Mn;YV2FPT0WU
SW837	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJzLkS5N\|kh\|ryP	MV3TRW5ITVJ?
SHP-77	NVjYNGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjtPFRqUUN3ME2yNU43OTJ{IN88US=>	NFz5XG5USU6JRWK=
DB	NEPWclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJzLk[xOFIh\|ryP	NW\UdIE3W0GQR1XS
ES5	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vZfWlEPTB;MkGuOlg3PCEQvF2=	MWHTRW5ITVJ?
COR-L23	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPSTWM2OD1{MT64NFUyKM7:TR?=	M2nGPHNCVkeHUh?=
KU-19-19	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moi2TWM2OD1{MT64PVgzKM7:TR?=	MUTTRW5ITVJ?
T84	NI[4NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv0XGJKSzVyPUKxMlk5OTlizszN	NGXtUnVUSU6JRWK=
NCI-H630	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXDcWpKSzVyPUKyMlU{PjNizszN	NYK5cXo1W0GQR1XS
LU-165	M3PucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTpbVZGUUN3ME2yNk42PTRizszN	NYe0UXh7W0GQR1XS
COLO-792	NEH3b5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\OSGxKSzVyPUKyMlcyOTFizszN	MkfPV2FPT0WU
CAL-62	NH7lN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3T4U2lEPTB;MkKuO\|UyPyEQvF2=	NXuy[4w4W0GQR1XS
HCE-T	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zFXmlEPTB;MkKuPFYxPiEQvF2=	MmD2V2FPT0WU
BB65-RCC	NWnufWZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnLNGM3UUN3ME2yN{4xOzR2IN88US=>	NUfCTXFkW0GQR1XS
SiHa	NHjuTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkS4TWM2OD1{Mz6zPVY5KM7:TR?=	MXPTRW5ITVJ?
NCI-H2081	NWX0d\|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XXTGlEPTB;MkSuNFY1OSEQvF2=	NIjDS49USU6JRWK=
U251	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJ2LkC2Olgh\|ryP	MkDqV2FPT0WU
LoVo	NFTPWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjQTWM2OD1{ND65NlgzKM7:TR?=	MY\TRW5ITVJ?
GCIY	NXvmS5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJ3LkK4O\|ch\|ryP	NIrkdGFUSU6JRWK=
NUGC-3	NI[2bpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnq2TWM2OD1{NT6zN\|E3KM7:TR?=	NGjCS5FUSU6JRWK=
LNCaP-Clone-FGC	NV;4dm94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXlRYdKSzVyPUK1MlM1QThizszN	M1vzZXNCVkeHUh?=
PA-1	M{PMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTJ3Lk[4N\|Mh\|ryP	NIjqNGFUSU6JRWK=
OE33	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVT4PFlmUUN3ME2yOU43QDV\|IN88US=>	NYf3fXNxW0GQR1XS
HT-29	NVHmfphsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;4TVJKSzVyPUK1Mlc5PzlizszN	MX;TRW5ITVJ?
RCM-1	NH;4fFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorpTWM2OD1{NT65OlU3KM7:TR?=	NIH1UnNUSU6JRWK=
NCI-H1522	M3;5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTJ3Lkm5NVEh\|ryP	MYDTRW5ITVJ?
LB373-MEL-D	M3q2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljVTWM2OD1{Nj6xO\|A5KM7:TR?=	M{jVXXNCVkeHUh?=
NCI-H1436	NYXPV3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXh[WJzUUN3ME2yOk4zPzN6IN88US=>	NYj1V3RvW0GQR1XS
COLO-824	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7wfYRKSzVyPUK2MlQxODJizszN	M1;OVnNCVkeHUh?=
CP50-MEL-B	M2PDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzXXlhKSzVyPUK2MlU3PzVizszN	NYTtUIdoW0GQR1XS
EGI-1	NWH1S3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3GSmFKSzVyPUK3MlI3QThizszN	M1OzSnNCVkeHUh?=
LAN-6	NHewOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvwc2tKSzVyPUK3MlM2QThizszN	M2\5WXNCVkeHUh?=
GAK	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTJ5LkSyNlUh\|ryP	MXrTRW5ITVJ?
MDA-MB-175-VII	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:2VItKSzVyPUK3MlUxPTNizszN	MkPsV2FPT0WU
JVM-2	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rPdmlEPTB;MkeuOlYzOiEQvF2=	M1XHNXNCVkeHUh?=
UACC-257	NYjoU5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TSbWlEPTB;MkeuOlg4QCEQvF2=	NGXuR4NUSU6JRWK=
SW1783	NWTremt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDjTWM2OD1{Nz63O\|g{KM7:TR?=	NFf4S3FUSU6JRWK=
HT-3	M3XUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJ6LkKxOlYh\|ryP	M{S2fXNCVkeHUh?=
RL	MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4O3S2lEPTB;MkiuOVkyOSEQvF2=	NEnKW29USU6JRWK=
TK10	NWfaS\|ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLNTWM2OD1{OD62OVM2KM7:TR?=	M{nEcnNCVkeHUh?=
HT55	NWLS[ppbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm4cYpmUUN3ME2yPU4xPTZ3IN88US=>	MmXnV2FPT0WU
BT-20	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHGTWM2OD1{OT6wOVg3KM7:TR?=	M{DGW3NCVkeHUh?=
TGBC24TKB	NFnXOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnZTWM2OD1{OT6xPFMyKM7:TR?=	MoDuV2FPT0WU
HSC-2	M2[4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn4NXVIUUN3ME2yPU4{ODBzIN88US=>	NXn6TFRMW0GQR1XS
COLO-205	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nndGlEPTB;MkmuN\|k1PCEQvF2=	NFvN[I5USU6JRWK=
GT3TKB	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXFOIVPUUN3ME2yPU43QDd5IN88US=>	NHLp[JdUSU6JRWK=
T47D	M3HINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKzTWM2OD1{OT64OVgzKM7:TR?=	NGjTPXJUSU6JRWK=
OMC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoD2TWM2OD1\|MD6xPVE6KM7:TR?=	MUfTRW5ITVJ?
PFSK-1	NVnoSWhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTNzLkK2OVkh\|ryP	M4Wxe3NCVkeHUh?=
JEG-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHJTWM2OD1\|MT6zOVYyKM7:TR?=	NWfteWVrW0GQR1XS
RD	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTNzLkWxNVUh\|ryP	NIfFcHNUSU6JRWK=
NCI-H64	NEfGRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTN{LkSxO\|kh\|ryP	NH;mUI5USU6JRWK=
DMS-114	NEXhW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDscoF5UUN3ME2zNk41OTh{IN88US=>	M4XyTXNCVkeHUh?=
NCI-H661	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3qzZ2lEPTB;M{KuOlUxOSEQvF2=	NELuc3dUSU6JRWK=
CAL-148	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPYT3RKSzVyPUOyMlY3PjVizszN	M4f5VHNCVkeHUh?=
HuP-T3	M3LEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPTcJNKSzVyPUOyMlk{OzhizszN	M2\Y[XNCVkeHUh?=
ES4	NYjQT5hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfZTWM2OD1\|Mz6xO\|A2KM7:TR?=	NVf5eGR2W0GQR1XS
Ca9-22	NI\1[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTN\|LkS2NFEh\|ryP	MX;TRW5ITVJ?
LP-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLsTWM2OD1\|ND6wPUDPxE1?	MXvTRW5ITVJ?
AU565	M{jHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTN2LkWwOlkh\|ryP	MWHTRW5ITVJ?
MDA-MB-453	M1\KOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfwR5BKSzVyPUO1MlE1OjZizszN	MUjTRW5ITVJ?
SNU-C1	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTN3LkG3NUDPxE1?	M3ToO3NCVkeHUh?=
SW13	NYPDTINrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTN3LkSwO\|Yh\|ryP	MV;TRW5ITVJ?
NCI-H2122	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnvSZFKSzVyPUO1MlU2QThizszN	NUm4UYxyW0GQR1XS
NCI-H1395	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr3U2xKSzVyPUO1MlY3QTFizszN	Mlm4V2FPT0WU
J-RT3-T3-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrqUG5OUUN3ME2zOk4xOjl2IN88US=>	NFnIe41USU6JRWK=
COR-L279	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTscpBsUUN3ME2zOk4yQThzIN88US=>	NVrxSZc2W0GQR1XS
ATN-1	M3HPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETOSGhKSzVyPUO2Mlg2OTZizszN	M1XKcXNCVkeHUh?=
HCC2998	NWXmeG9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHlTWM2OD1\|Nj64OVcyKM7:TR?=	NGLXXYJUSU6JRWK=
UM-UC-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\vTWM2OD1\|Nj64Olc2KM7:TR?=	MkfCV2FPT0WU
DV-90	NEf5U\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon4TWM2OD1\|Nj65NFY4KM7:TR?=	NXfxcW1iW0GQR1XS
ES8	NEHiclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH2eolPUUN3ME2zOk46OzF6IN88US=>	NVvJVW9LW0GQR1XS
YAPC	M4jZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fjXWlEPTB;M{[uPVY2PCEQvF2=	MV7TRW5ITVJ?
HCC1599	NVfiRolqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXGTWM2OD1\|Nz6xOlE5KM7:TR?=	NWfRPI1IW0GQR1XS
UMC-11	NE\JNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTN5LkK1NFMh\|ryP	NXnDW2ZFW0GQR1XS
THP-1	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPiTWM2OD1\|Nz6yPFY5KM7:TR?=	NFXrbJVUSU6JRWK=
OCUB-M	NHG5N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTOdWhRUUN3ME2zO{4zQDlzIN88US=>	MmX5V2FPT0WU
NCI-H1693	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlq0TWM2OD1\|Nz6zNlM{KM7:TR?=	NHTp[W1USU6JRWK=
NCI-H345	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DZUGlEPTB;M{euN\|YzPCEQvF2=	NITKU\|hUSU6JRWK=
COLO-800	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTN5LkW2O{DPxE1?	M{ixWHNCVkeHUh?=
COLO-320-HSR	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\2e4NHUUN3ME2zPE4{PDl{IN88US=>	Mn3nV2FPT0WU
NCI-H596	MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTN6LkS0PFkh\|ryP	MXfTRW5ITVJ?
NCI-H187	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHoTWM2OD1\|OD63N\|Q1KM7:TR?=	M1XmdXNCVkeHUh?=
ECC4	M3rpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXtNJF1UUN3ME2zPU4xQDF2IN88US=>	NVexd5dCW0GQR1XS
KP-4	NIr2XWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjNNnZKSzVyPUO5MlEzOzVizszN	MkLyV2FPT0WU
NCI-H2227	NF7ISHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTN7LkO5OFkh\|ryP	NWqySXpoW0GQR1XS
22RV1	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3yS5JiUUN3ME2zPU45Ozl6IN88US=>	MnrtV2FPT0WU
SAS	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTRyLkC5OkDPxE1?	Mnr3V2FPT0WU
PANC-10-05	M{j0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTRyLkG4Nlgh\|ryP	MXTTRW5ITVJ?
MDA-MB-468	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPkTWM2OD12MD61N\|Q3KM7:TR?=	NYjWZ\|JFW0GQR1XS
RPMI-7951	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfkc3pKSzVyPUSxMlIxPzVizszN	M1vyO3NCVkeHUh?=
BB49-HNC	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\pNZVXUUN3ME20NU4zOTd7IN88US=>	M1LFVHNCVkeHUh?=
23132-87	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPGWYlKSzVyPUSxMlI4OzJizszN	NIjiRVVUSU6JRWK=
HCC1569	NHXPenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGf2botKSzVyPUSxMlI5QDVizszN	M3foUHNCVkeHUh?=
CP66-MEL	NInJSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;BXo1XUUN3ME20Nk4yQDh4IN88US=>	NWLEXlR[W0GQR1XS
K-562	NF2zZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnWwTWM2OD12Mj6yPFU1KM7:TR?=	MnuzV2FPT0WU
OCI-AML2	M4LROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r0OWlEPTB;NEKuPFk4PCEQvF2=	NFnYUYNUSU6JRWK=
SW756	NFXyRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTR\|LkCzPFgh\|ryP	NXPjTZMyW0GQR1XS
M14	M{O5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nZSWlEPTB;NEOuN\|E5QSEQvF2=	M1TXW3NCVkeHUh?=
NCI-H1623	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\KTWM2OD12Mz60OlQh\|ryP	NFH3bVdUSU6JRWK=
KNS-81-FD	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrQeno4UUN3ME20N{44PjJizszN	MlS4V2FPT0WU
TGBC1TKB	NY\P[lRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jI[2lEPTB;NEOuPVA6QSEQvF2=	MnHpV2FPT0WU
RERF-LC-MS	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnoTWM2OD12Mz65NlgyKM7:TR?=	MWTTRW5ITVJ?
PC-3	NI\ScW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:wTJdtUUN3ME20OE41OzR5IN88US=>	NVe3eoxMW0GQR1XS
HuP-T4	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PjPGlEPTB;NESuOFQ4PCEQvF2=	NWLkd5RsW0GQR1XS
NCI-H510A	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7iemU3UUN3ME20OE44ODhizszN	M3LyW3NCVkeHUh?=
LB2518-MEL	M4\UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjUflFKSzVyPUS0Mlc6OzdizszN	MlfUV2FPT0WU
TE-5	NITGXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTR3Lkm1PFEh\|ryP	Ml7DV2FPT0WU
EW-24	NHS5UmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTR4LkG3NlMh\|ryP	MUHTRW5ITVJ?
LB647-SCLC	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTR4LkKxOVUh\|ryP	MXHTRW5ITVJ?
NCI-H524	M2\JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zhZmlEPTB;NE[uO\|E5PSEQvF2=	NHL3SoxUSU6JRWK=
EW-11	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPibXBKSzVyPUS2Mlk{PzNizszN	M4XTfXNCVkeHUh?=
KALS-1	NVf1VoZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHUPVFJUUN3ME20O{4zODZ4IN88US=>	MWDTRW5ITVJ?
BT-474	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjTbolrUUN3ME20O{41OjF4IN88US=>	NVfHe45ZW0GQR1XS
SK-N-AS	M1z5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLtTZJOUUN3ME20O{45QDhizszN	NFnQOY9USU6JRWK=
HCC2157	NUjwVGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnOwTWM2OD12OD6wO\|Yh\|ryP	MXTTRW5ITVJ?
HCC1954	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzLUnFwUUN3ME20PE4yPzB2IN88US=>	MoT4V2FPT0WU
FADU	NYn4W\|ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\0TWM2OD12OD6zNFMyKM7:TR?=	MYXTRW5ITVJ?
S-117	NX2ySmprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlewTWM2OD12OD6zPFE2KM7:TR?=	MnLuV2FPT0WU
LS-1034	MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTR6LkewOlch\|ryP	MoX4V2FPT0WU
CAMA-1	NEeyb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDz[XBZUUN3ME20PU42PTR\|IN88US=>	NIH5T3dUSU6JRWK=
LU-134-A	M3TXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvtTWM2OD12OT64NFg2KM7:TR?=	MkWxV2FPT0WU
NCI-H1838	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rMNmlEPTB;NEmuPFA5PyEQvF2=	M3[xd3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

体内研究

Ponatinib抑制取自FLT3-ITD阳性AML病人的原代白血病细胞，而不抑制表达阴性FLT3的AML病人的白血病细胞。^[3]

激酶实验：^[1]	- 合并激酶实验: 通过同质时间分辨荧光共振能量转移法(TR-FRET)，使用纯化的人类野生型ABL激酶，T315I突变型ABL激酶，及生物素化的磷酸激酶底物肽: 生物素-EKKMAAEAIYAAPFAK-NH2，测定野生型ABL和T315I突变型ABL活性的抑制激酶反应在全LANCE激酶buffer (LKB)中进行，LKB包括20 mM NaHEPES（pH 为7.4）, 0.1 mg ⁄ mL BSA, 1 mM ATP, 10 mM MgCl₂, 及0.41 mM DTT，在提前用1% BSA（溶于PBS）包被的96孔板上4^oC下过夜。用于激酶反应，Ponatinib稀释物和野生型ABL, T315I突变型ABL (40 pM), 及底物肽(50 nM), 在室温下温育1小时（T315I突变型ABL）或2小时（野生型ABL）。加入15 nM 抑制剂, 6 nM 铕标记的磷酸酪氨酸抗体（磷酸化位点在第66为酪氨酸上），及60 nM 别藻蓝素标记的链酶亲和素，终止反应。实验板在室温下黑暗温育20分钟，使用Wallac Victor2V读数器读取615和665nm处的荧光值。在孔中数据平均值中插入抑制剂的3倍连续稀释液，再读取665nm处荧光值，计算IC50值。
细胞实验：^[1]	- 合并 Cell lines: Ba ⁄ F3细胞 Concentrations: 0-625 nM, 和0-10 µM Incubation Time: 72小时 Method: Ba/F3细胞系按每孔4×10³个细胞分布在96孔板上(4×10³)，和梯度浓度Ponatinib温育72小时。Ponatinib浓度范围为: 0-625 nM 作用于表达BCR-ABL细胞，0-10 µM 用于测定BCR-ABL阴性细胞。使用MTS实验测定细胞增殖，取三次平行实验平均值测定IC50值。 (Only for Reference)
动物实验：^[3]	- 合并 Animal Models: 皮下植入MV4-11细胞移植瘤(1×10⁷，50%基质胶中) 的雌性CB.17 SCID鼠 Dosages: 每天处理一次，持续4周 Administration: 口服饲喂处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ponatinib (AP24534) SDF

分子量	532.56
化学式	C₂₉H₂₇F₃N₆O
CAS号	943319-70-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	November 22 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
回答：
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

选择性强的Bcr-Abl抑制剂

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
活性最高的Bcr-Abl抑制剂

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA批准的Bcr-Abl抑制剂

Dasatinib : Approved by FDA for CML and Ph+ ALL.
最新的Bcr-Abl抑制剂

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

研究领域

产品类型

定制您的化合物库

Ponatinib (AP24534)

客户使用Selleck生产的Ponatinib (AP24534)发表文献101篇：

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ponatinib (AP24534) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

常见问题及建议解决方法

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

相关Bcr-Abl产品